Dementia is an umbrella term for a decline in memory, reasoning, language, judgment, or other thinking abilities that becomes severe enough to interfere with daily life. Alzheimer’s disease is the most common cause, but vascular disease, Lewy body disease, frontotemporal degeneration, mixed dementia, and other conditions can also produce dementia symptoms.
The seven stages of dementia usually refer to the Global Deterioration Scale developed by Dr. Barry Reisberg and colleagues. This framework describes a continuum from no noticeable cognitive impairment to very severe cognitive and physical decline. It is one of several staging systems, and symptoms, progression, and care needs can differ considerably from one person to another.
Laboratory testing cannot determine a person’s dementia stage by itself. Blood and urine tests may instead help identify thyroid disorders, vitamin deficiencies, anemia, infections, metabolic abnormalities, inflammation, and other conditions that may cause, resemble, or worsen cognitive symptoms.
Through Ulta Lab Tests’ Cognitive Health testing category, patients can explore relevant laboratory testing and use their results to support more informed conversations with qualified healthcare professionals.
Medical disclaimer: This article is for educational purposes only. Laboratory testing provides health information but does not replace professional evaluation, diagnosis, treatment, or emergency medical care.
Dementia describes a syndrome rather than one specific disease. It involves a decline in one or more cognitive abilities, including:
Memory loss alone does not necessarily mean that someone has dementia. Poor sleep, depression, medication effects, hearing loss, vision impairment, vitamin deficiencies, thyroid disease, infections, metabolic disturbances, alcohol use, and other medical conditions may affect thinking or memory.
A dementia diagnosis generally requires evidence that cognitive decline is interfering with independent functioning. Healthcare professionals therefore consider not only cognitive test results but also whether a person can manage medications, finances, transportation, meals, appointments, hygiene, communication, and household responsibilities.
Direct answer: The seven stages are no cognitive decline, very mild cognitive decline, mild cognitive decline, moderate cognitive decline, moderately severe cognitive decline, severe cognitive decline, and very severe cognitive decline.
The Global Deterioration Scale was developed to describe cognitive and functional decline associated primarily with degenerative dementias such as Alzheimer’s disease. Stages 1 through 3 are often considered pre-dementia stages, while stages 4 through 7 describe increasing levels of dementia and dependence.
The model does not perfectly describe every form of dementia. Vascular dementia may progress in a stepwise pattern. Lewy body dementia can involve pronounced fluctuations, movement symptoms, visual hallucinations, or sleep disturbances. Frontotemporal dementia may initially affect behavior or language more than memory. Mixed dementia can combine features of several conditions.
| Stage | General Description | Typical Cognitive or Functional Changes | Common Support Needs |
|---|---|---|---|
| Stage 1 | No cognitive decline | No noticeable memory, reasoning, or functional difficulties | Routine preventive healthcare and attention to new concerns |
| Stage 2 | Very mild cognitive decline | Occasional word-finding difficulty, misplaced objects, or subjective forgetfulness | Monitoring and review of sleep, stress, hearing, medications, and general health |
| Stage 3 | Mild cognitive decline | Noticeable difficulty with concentration, organization, learning names, work performance, or remembering information | Clinical evaluation, safety review, and assistance with complex tasks when needed |
| Stage 4 | Moderate cognitive decline or mild dementia | Difficulty managing finances, planning meals, following current events, traveling independently, or completing complex tasks | Help with finances, medications, transportation, legal planning, and household organization |
| Stage 5 | Moderately severe cognitive decline or moderate dementia | Confusion about time or location, major memory gaps, and difficulty choosing appropriate clothing | Regular assistance with daily routines and increased supervision |
| Stage 6 | Severe cognitive decline | Extensive memory loss, sleep disruption, personality or behavioral changes, wandering, and difficulty with dressing or toileting | Close supervision, personal-care assistance, home-safety measures, and caregiver support |
| Stage 7 | Very severe cognitive decline or late-stage dementia | Limited speech, loss of mobility, impaired swallowing, and inability to complete basic self-care | Continuous assistance, swallowing and nutrition assessment, comfort-focused care, and advanced-care planning |
These descriptions are general guides, not a timetable. A person may have characteristics from more than one stage, remain stable for an extended period, or decline differently because of infection, hospitalization, stroke, medication effects, delirium, or another health condition.
At stage 1, no memory or thinking impairment is apparent to the person, family members, or healthcare professionals. The individual can generally work, drive, manage finances, communicate, and perform daily activities independently.
Stage 1 does not mean that everyone is experiencing the biological beginning of a brain disease. It simply means the clinical scale detects no cognitive impairment. Although biological changes associated with Alzheimer’s disease can begin before symptoms, specialized biomarker testing is not intended as routine screening for every symptom-free adult.
Helpful actions include maintaining preventive healthcare, addressing hearing or vision impairment, managing cardiovascular and metabolic risk factors, and discussing significant family or medical concerns with a healthcare professional.
Stage 2 may involve mild lapses such as forgetting a familiar word, losing keys, or having trouble recalling a name. These experiences may reflect normal aging, stress, fatigue, poor sleep, medication effects, or the earliest signs of a cognitive disorder.
Symptoms at this stage generally do not interfere with work or independent living and may not be apparent during a brief clinical examination. Persistent or worsening changes, particularly those noticed by family members, should be discussed with a healthcare professional.
At stage 3, cognitive changes become more noticeable. A person may have difficulty retaining information, finding words, organizing projects, navigating unfamiliar places, or performing as efficiently at work.
This stage may correspond with mild cognitive impairment, or MCI. People with MCI have noticeable and sometimes measurable cognitive changes but remain independent in most daily activities. MCI has several possible causes, and not everyone with MCI develops dementia. Symptoms may remain stable, improve, or progress depending on the underlying cause.
A comprehensive evaluation during this stage may help identify medication effects, depression, sleep apnea, nutritional deficiencies, thyroid dysfunction, hearing loss, or other contributors. It can also establish a baseline for monitoring changes over time.
Stage 4 is commonly considered the point at which mild dementia becomes clinically evident. A person may have trouble managing bills, following complex instructions, planning meals, remembering recent events, or organizing travel.
Basic self-care often remains intact, but complex daily activities become harder. The individual may withdraw from challenging conversations or situations because they recognize their difficulties.
This is an important stage for discussing transportation, medication management, financial safeguards, advance directives, home safety, caregiver responsibilities, and the possible need for evaluation by a neurologist, geriatrician, or memory specialist.
Major gaps in memory and orientation become more apparent during stage 5. The person may forget an address, telephone number, date, season, or current location. Assistance may be needed to select suitable clothing or maintain a daily schedule.
Many people still recognize close family members and retain important information about themselves. Eating and toileting may remain largely independent, although supervision and structured routines become increasingly important.
Stage 6 often brings extensive memory impairment and increasing dependence. The person may need help dressing, bathing, toileting, eating, and completing other personal-care activities. Sleep-wake patterns may become disrupted.
Behavioral or psychological changes may include anxiety, suspiciousness, agitation, hallucinations, repetitive actions, or wandering. A sudden or dramatic behavioral change should be medically evaluated rather than assumed to be routine dementia progression. Pain, dehydration, constipation, infection, medication effects, and other illnesses can cause abrupt worsening.
Caregiver support, wandering precautions, fall prevention, medication supervision, home-safety planning, and respite care become especially important.
During stage 7, speech, movement, swallowing, and awareness of the environment may become profoundly impaired. The person usually requires assistance with eating, hygiene, transfers, toileting, mobility, and nearly all daily activities.
Care planning may involve swallowing and nutrition evaluation, pressure-injury prevention, mobility support, comfort measures, caregiver assistance, and discussions about goals of care. Families may benefit from palliative-care or hospice consultation when clinically appropriate.
Understanding dementia stages may help families anticipate changes, but a stage should never replace an individualized assessment. Staging can help guide conversations about:
The most meaningful question is often not simply, “What stage is this?” but, “Which abilities remain, which activities are becoming unsafe, and what support would preserve dignity and independence?”
Laboratory tests do not prove that a symptom is caused by dementia. They may help identify another medical issue that deserves attention or may be contributing to cognitive symptoms.
| Symptom or Risk Factor | What It May Suggest | Related Laboratory Tests |
|---|---|---|
| Gradually worsening memory or executive function | Neurological disease, medication effects, endocrine dysfunction, or nutritional contributors | Complete Blood Count with Differential and Platelets, Comprehensive Metabolic Panel, TSH Test, Vitamin B12 Test, Folate Serum Test, and Homocysteine Test |
| Fatigue, weakness, pallor, or slowed thinking | Anemia, nutrient deficiency, thyroid dysfunction, or chronic illness | Complete Blood Count with Differential and Platelets, Ferritin Test, Iron and Total Iron Binding Capacity Test, TSH Test, Vitamin B12 Test, and Folate Serum Test |
| Numbness, tingling, balance problems, or an abnormal gait | Vitamin B12 deficiency or a neurological condition | Vitamin B12 Test, Methylmalonic Acid Test, and Folate Serum Test |
| Confusion with vomiting, dehydration, or medication changes | Electrolyte, glucose, kidney, liver, or medication-related abnormalities | Comprehensive Metabolic Panel and Glucose Test |
| Diabetes, hypertension, high cholesterol, or cardiovascular disease | Vascular risk factors that may contribute to cognitive impairment | Hemoglobin A1c Test, Glucose Test, Lipid Panel Test, and Comprehensive Metabolic Panel |
| Heavy alcohol use, prolonged vomiting, or severe malnutrition | Thiamine deficiency, liver dysfunction, or electrolyte abnormalities | Vitamin B1 Blood Test and Comprehensive Metabolic Panel |
| Relevant infection exposure or risk factors | HIV, syphilis, or another infection affecting neurological health | HIV Testing and Syphilis RPR Test, when clinically appropriate |
| New urinary symptoms accompanied by acute confusion | A urinary or systemic illness that requires clinical evaluation | Urinalysis Complete Test and Urine Culture Test, when clinically indicated |
| Known occupational or environmental exposure | A possible toxic contribution | Exposure-specific testing selected according to the substance and exposure history |
Safety note: Dementia generally develops gradually. Confusion that begins suddenly over hours or days may represent delirium, stroke, infection, severe glucose or electrolyte abnormalities, medication toxicity, or another urgent condition.
Call emergency services for sudden confusion, especially when it occurs with facial drooping, weakness, difficulty speaking, severe headache, fainting, fever, seizure, breathing difficulty, chest pain, or loss of consciousness. Do not delay emergency care while waiting for direct-access laboratory testing.
Direct answer: Laboratory testing does not stage dementia, but it may identify medical conditions that cause, resemble, or worsen memory and thinking problems.
Laboratory testing may help patients and healthcare professionals investigate questions such as:
A baseline laboratory evaluation for persistent cognitive symptoms may include a Complete Blood Count with Differential and Platelets, Comprehensive Metabolic Panel, TSH Test, Vitamin B12 Test, Homocysteine Test, C-Reactive Protein Test, and Sed Rate Test. Additional tests should be selected according to the person’s history, examination, symptoms, and risk factors.
Routine laboratory testing cannot independently:
| Laboratory Test | What It Measures | Why It May Be Relevant | Important Limitations |
|---|---|---|---|
| Complete Blood Count with Differential and Platelets | Red blood cells, hemoglobin, white blood cells, platelets, and related indices | Low hemoglobin may indicate anemia. Abnormal white-cell results may accompany infection, inflammation, or other conditions. | The results are nonspecific and do not diagnose dementia. |
| Comprehensive Metabolic Panel | Glucose, electrolytes, calcium, kidney markers, liver markers, and proteins | Abnormal sodium, calcium, glucose, kidney function, or liver function can affect cognition or mental status. | A normal result does not exclude neurological disease. |
| TSH Test | Thyroid-stimulating hormone | A high or low result may indicate thyroid dysfunction that can influence energy, mood, concentration, and thinking. | Illness, medications, supplements, and pituitary conditions may affect interpretation. Additional thyroid testing may be needed. |
| Vitamin B12 Test | Circulating vitamin B12, also called cobalamin | A low result may support vitamin B12 deficiency, which can affect blood cells, nerves, balance, and cognition. | A borderline result may require a Methylmalonic Acid Test or other follow-up. |
| Folate Serum Test | Folate concentration in serum | A low result may indicate deficiency contributing to anemia or neurological symptoms. | Results should be interpreted with vitamin B12 status, diet, supplements, and medical history. |
| Methylmalonic Acid Test | A metabolic marker affected by vitamin B12 availability | An elevated result may support functional vitamin B12 deficiency, including in some people with borderline serum B12 results. | Kidney impairment may elevate methylmalonic acid independently of vitamin B12 status. |
| Homocysteine Test | Homocysteine concentration in blood | An elevated result may accompany vitamin B12, folate, or vitamin B6 deficiency and may also relate to kidney function or vascular health. | Homocysteine is nonspecific and should not be used alone to identify the cause of cognitive decline. |
| C-Reactive Protein Test | Systemic inflammatory activity | An elevated result suggests inflammation somewhere in the body and may support further evaluation. | It does not determine the cause or location of inflammation. |
| Sed Rate Test | The rate at which red blood cells settle in a blood sample | A faster rate may occur with inflammatory or systemic illness. | Age, anemia, pregnancy, and other factors can influence the result. |
| Hemoglobin A1c Test | Average blood glucose exposure over approximately two to three months | A high result may support diabetes or impaired glucose regulation, both of which are relevant to vascular health. | Some blood disorders, kidney disease, pregnancy, and altered red-cell turnover may affect the result. |
| Lipid Panel Test | Total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides | Abnormal lipid levels may contribute to cardiovascular and cerebrovascular risk. | The test does not diagnose cognitive impairment or dementia. |
| Vitamin B1 Blood Test | Blood thiamine concentration | Low thiamine may be relevant in severe malnutrition, prolonged vomiting, malabsorption, or heavy alcohol use. | Testing should be guided by clinical risk and must not delay urgent evaluation or treatment when severe deficiency is suspected. |
| HIV Testing | HIV antigens, antibodies, or viral material, depending on the selected test | HIV testing may be considered when exposure history, symptoms, or risk factors justify it. | Test selection and interpretation depend on exposure timing and the specific testing method. Reactive screening results require appropriate follow-up. |
| Syphilis RPR Test | Nontreponemal antibodies that may be present with syphilis | Testing may be considered when history, symptoms, or risk factors support evaluation. | Reactive screening results require appropriate confirmatory testing and clinical interpretation. |
| Urinalysis Complete Test | Physical, chemical, and microscopic characteristics of urine | It may provide useful information when acute confusion occurs with urinary symptoms or other clinical concerns. | An abnormal result does not automatically mean a urinary finding caused the cognitive change. |
| Urine Culture Test | Bacterial or yeast growth in urine | It may help evaluate a suspected urinary infection when symptoms or clinical findings support testing. | Bacterial growth can represent contamination or asymptomatic bacteriuria and must be interpreted in clinical context. |
Blood-based Alzheimer’s biomarkers are a rapidly developing area of medicine. The FDA has cleared blood assays intended to aid qualified healthcare professionals in evaluating Alzheimer’s-related amyloid pathology in certain adults with cognitive symptoms.
These specialized tests may measure biomarkers such as phosphorylated tau or relationships between tau and beta-amyloid. They are different from routine tests used to investigate nutritional, thyroid, metabolic, inflammatory, or infectious contributors to cognitive symptoms.
Alzheimer’s blood biomarkers are not intended to function as stand-alone dementia diagnoses or universal screening tests for symptom-free adults. Results must be interpreted with clinical history, objective cognitive assessment, neurological evaluation, and other relevant information. Some tests are intended primarily for specialty-care settings, while others may help clinicians determine whether additional Alzheimer’s evaluation is appropriate.
Because product indications, availability, clinical guidance, and regulatory notices can change, the exact test and its current intended use should be verified before publication, ordering, or clinical interpretation.
Testing should be individualized. Not everyone with memory concerns needs every available test.
For a person with persistent or worsening cognitive symptoms, an initial evaluation may include:
A healthcare professional may add, remove, or modify tests based on age, symptoms, medications, medical conditions, previous results, and physical-examination findings.
Depending on the initial results and medical history, additional testing may include:
These tests may help identify deficiencies, anemia, or vascular and metabolic risk factors. An abnormal result should not automatically be assumed to explain every cognitive symptom.
Targeted testing should address a specific clinical question. Examples include:
Broad, indiscriminate testing can produce incidental or misleading findings and is not a substitute for a focused medical assessment.
A neurologist, geriatrician, memory specialist, or other qualified clinician may recommend:
Discuss laboratory testing and a clinical evaluation when:
Direct-access testing may provide useful objective information, but significant changes in memory, behavior, judgment, or daily functioning still require professional evaluation.
A laboratory reference range represents values observed in a comparison population using a particular testing method. A result outside the range does not automatically establish disease, and a result within the range does not guarantee that a health condition is absent.
Interpretation may be affected by:
For example, a borderline Vitamin B12 Test result may lead to a Methylmalonic Acid Test. An abnormal TSH Test may lead to further thyroid evaluation, such as a TSH and Free T4 Test. An elevated C-Reactive Protein Test or Sed Rate Test result may justify evaluation for many possible inflammatory causes.
Trends may be helpful when testing is repeated under comparable conditions. However, repeat testing should address a clear clinical question rather than follow an arbitrary schedule.
Ulta Lab Tests allows patients to order many laboratory tests directly online where available. Patients can review transparent pricing before ordering, and insurance is not required. Eligible HSA or FSA payment may be accepted.
Specimen collection is performed through established laboratory networks, such as Quest Diagnostics where applicable, and results are delivered through a secure online account. Patients can share their results with a qualified healthcare professional and use them to support more informed conversations about nutritional, thyroid, metabolic, inflammatory, infectious, and vascular factors that may affect cognitive health.
Ulta Lab Tests does not replace a dementia evaluation, neurological examination, cognitive assessment, brain imaging, specialist-directed biomarker testing, or emergency medical care.
Explore Cognitive Health Tests from Ulta Lab Tests
The seven stages are no cognitive decline, very mild cognitive decline, mild cognitive decline, moderate cognitive decline, moderately severe cognitive decline, severe cognitive decline, and very severe cognitive decline. The stages describe general changes in cognition, independence, behavior, and physical function, but people do not always progress through them uniformly.
Within the seven-stage framework, stages 1 through 3 are generally considered pre-dementia stages. Stage 3 may correspond to mild cognitive impairment. Dementia generally becomes clinically apparent around stage 4, when cognitive decline begins interfering with complex independent activities such as managing finances, planning meals, organizing travel, or following detailed instructions.
No. Mild cognitive impairment causes noticeable and sometimes measurable changes in memory or other thinking abilities, but the person generally remains independent in most daily activities. Dementia involves cognitive decline severe enough to interfere with daily functioning. Some people with mild cognitive impairment progress to dementia, while others remain stable or improve.
Routine blood tests cannot independently diagnose or stage dementia. They may identify anemia, thyroid dysfunction, vitamin deficiencies, metabolic abnormalities, inflammation, or infections that can affect cognition. Selected Alzheimer’s blood biomarkers may help qualified clinicians evaluate Alzheimer’s-related pathology in appropriate symptomatic patients, but they are not stand-alone diagnoses or universal screening tests.
A baseline evaluation may include a Complete Blood Count with Differential and Platelets, Comprehensive Metabolic Panel, TSH Test, Vitamin B12 Test, Homocysteine Test, C-Reactive Protein Test, and Sed Rate Test. Other tests may be added according to symptoms and risk factors.
Vitamin B12 deficiency can cause memory changes, slowed thinking, fatigue, anemia, numbness, balance problems, or other neurological symptoms. A Vitamin B12 Test can help evaluate deficiency, although a borderline result may require a Methylmalonic Acid Test. Correcting a deficiency does not necessarily reverse cognitive decline caused by an unrelated neurological disease.
Both underactive and overactive thyroid conditions can affect energy, mood, concentration, sleep, and thinking. A TSH Test is commonly used as an initial thyroid test. A TSH and Free T4 Test or other thyroid testing may be appropriate for clarification. An abnormal result does not prove that thyroid disease is the only cause of cognitive symptoms.
There is no fixed duration for any stage. Progression depends on the underlying condition, age, general health, vascular disease, infections, medication effects, and many other factors. A person may remain stable for an extended period or decline more quickly following illness or hospitalization. Stage descriptions guide planning but cannot predict an exact timeline.
Ulta Lab Tests allows patients to order many routine laboratory tests directly online where available. However, testing for memory loss should complement, not replace, a professional medical evaluation. Some specialized Alzheimer’s biomarkers require clinician or specialist involvement. Sudden confusion, neurological deficits, or rapid decline require urgent medical care rather than routine direct-access testing.
Confusion that begins suddenly over hours or days is not typical gradual dementia progression. Emergency evaluation is especially important when confusion occurs with weakness, facial drooping, speech problems, severe headache, fever, fainting, seizure, breathing difficulty, or loss of consciousness. Possible causes include stroke, infection, delirium, severe glucose abnormalities, electrolyte disturbances, or medication toxicity.
Repeat testing depends on the initial result, symptoms, medical history, treatment, and the healthcare professional’s follow-up plan. Vitamin deficiencies, thyroid abnormalities, anemia, diabetes, kidney function, and liver function may require monitoring. Frequently repeating normal tests without a clinical reason is unlikely to show whether dementia has progressed because staging primarily depends on cognitive and functional changes.
Bring a current medication and supplement list, previous laboratory and imaging results, a timeline of symptoms, relevant medical history, and examples of changes in daily functioning. A trusted family member or care partner can provide useful observations about finances, medications, driving, appointments, cooking, communication, falls, sleep, behavior, or personal care.
The seven stages of dementia provide a useful framework for describing the progression from normal cognition through mild cognitive impairment, increasing loss of independence, and very severe cognitive and physical decline. The stages are general guides and cannot fully capture every person’s experience or every type of dementia.
Laboratory testing cannot determine a dementia stage, but it may help identify vitamin deficiencies, thyroid dysfunction, anemia, metabolic abnormalities, inflammation, vascular risk factors, infections, and other conditions that may contribute to cognitive symptoms.
Through Ulta Lab Tests’ Cognitive Health testing options, patients can access relevant laboratory testing with transparent pricing and secure online results. Laboratory findings and persistent changes in memory, thinking, behavior, judgment, or daily functioning should be reviewed with a qualified healthcare professional as part of a complete cognitive evaluation.
Definition: The seven stages of dementia refer to the Global Deterioration Scale, which describes cognitive and functional decline from no impairment to very severe dementia. The stages are general guides and are most closely associated with progressive degenerative dementias such as Alzheimer’s disease.
Related laboratory tests: Complete Blood Count with Differential and Platelets, Comprehensive Metabolic Panel, TSH Test, Vitamin B12 Test, Folate Serum Test, Methylmalonic Acid Test, Homocysteine Test, C-Reactive Protein Test, Sed Rate Test, Hemoglobin A1c Test, Lipid Panel Test, and Vitamin B1 Blood Test.
How Ulta Lab Tests helps: Ulta Lab Tests provides direct online access to many routine laboratory tests with transparent pricing and secure online results.
Disclaimer: Laboratory testing is informational and should be interpreted with a qualified healthcare professional as part of a complete cognitive evaluation.
These tests provide information about blood-cell health, anemia, electrolytes, glucose, and kidney and liver markers; they do not diagnose or stage dementia.
The TSH page and combined TSH/free T4 page are current Ulta Lab Tests products.
These pages cover the nutritional and metabolic biomarkers discussed in the article.
Ulta Lab Tests also offers combined iron panels, but the individual products above match the tests named in the article.
These products evaluate blood glucose regulation and lipid-related cardiovascular risk factors discussed in the article.
Both are nonspecific inflammatory-marker tests and must be interpreted in clinical context.
These tests should be considered according to symptoms, history, and exposure risk rather than ordered routinely for every person with memory concerns.
The urinalysis and urine culture are linked separately, avoiding a reflex test and allowing each product to be presented independently.
Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)
